Business & Industry

AstraZeneca has agreed to license experimental obesity and metabolic disease drugs from China’s CSPC Pharmaceutical Group under the AstraZeneca CSPC weight-loss deal, with total potential payments reaching $18.5 billion. The agreement includes $1.2 billion paid upfront, with up to $17.3...

The rapid emergence of interconnected sensors, wearable devices, and remote-control instrumentation is fundamentally changing the landscape of pharmaceutical research. By creating a responsive and data-rich environment, these innovations allow for greater precision in experimental monitoring and a more comprehensive understanding of complex biological systems, paving the way for more effective therapeutic outcomes.

Over more than ten years working in healthcare, medical manufacturing, and life sciences, it’s clear how much the industry has developed and adapted. One of the biggest shifts has been the focus on sustainability. What used to be a...

Bringing a pharmaceutical product to market is hard work. Pre-market regulatory requirements in the United States and the European Union are well established and generally well understood by experienced development teams. And it still years and millions of dollars...

Novartis has entered into a licensing agreement with SciNeuro Pharmaceuticals focused on improving drug delivery to the brain. The Novartis and SciNeuro brain shuttle deal is valued at up to $1.7 billion and centers on an antibody-based program designed...

A number of regulatory changes have been released by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to facilitate clinical research in the country. In order to expedite study approvals while maintaining patient safety, the UK clinical trial...

Asia-Pacific’s biotechnology landscape is not just growing it is transforming. In 2026, the region stands at a unique crossroads where scientific ambition meets real-world demands. This year will test the industry’s resilience, shape global health priorities, and redefine how...